Treatment with coumarin to prevent or delay recurrence of malignant melanoma
- PMID: 8132701
- PMCID: PMC12201200
- DOI: 10.1007/BF01377122
Treatment with coumarin to prevent or delay recurrence of malignant melanoma
Abstract
Both coumarin (1,2-benzopyrone) and warfarin (4-hydroxycoumarin) have been shown to prevent the recurrence of malignant melanoma. Their action is macrophage-dependent and the dosage is critical. In 1984 a multicentre, prospective, randomised, double-blind trial of coumarin, given as a daily 50-mg dose for 2 years after surgery in patients with high-risk melanoma, was started. the patients had lesions greater than 1.70 mm thick and TNM stage IB or stage II disease. To date there are 4 recurrences in the coumarin-treated group of 13 patients, and 10 recurrences in the placebo-treated group of 14 patients (P < 0.01). There were no toxic effects.
References
-
- Cox D, O'Kennedy R, Thornes RD (1989) The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum Toxicol 8:501–506 - PubMed
-
- Daly L, Bourke GJ, McGilvray J (1991) Interpretation and uses of medical statistics, 4th edn. Blackwell, Oxford, p 208
-
- Day CL Jr, Lew RA, Milm MC, Harris MN, Kopf AW, Sober AJ, Fitzpatrick TB, (1981) The natural breakpoints for primary tumour thickness in clinical stage I melanoma. N Engl J Med 305:1155 - PubMed
-
- Marshall EM, Mohler JL (1993) Treatment of renal cell carcinoma with coumarin: a review. J Ir Coll Physicians Surg 22:6–9
-
- Moran E, Prosser E, O'Kennedy R, Thornes D (1993) The effect of coumarin and 7-hydroxycoumarin on the growth of human tumour cell lines. J Ir Coll Physicians Surg 22:41–43
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical